Abbott reported first-quarter 2026 sales of 11.16 billion dollars, an increase of 7.8 percent on a reported basis and 3.7 percent on a comparable basis versus the prior-year period. Comparable growth includes the prior and current year sales of Exact Sciences and excludes foreign exchange effects and certain structural heart compensation payments. First-quarter GAAP diluted earnings per share (EPS) were 0.61 dollars, and adjusted diluted EPS, which excludes specified items, were 1.15 dollars, reflecting 6 percent growth year over year.
On March 23, 2026, Abbott completed its acquisition of Exact Sciences, adding a cancer diagnostics portfolio that is now reported within the company’s Diagnostics segment as Cancer Diagnostics. Abbott projects full-year 2026 comparable sales growth of 6.5 to 7.5 percent and adjusted diluted EPS of 5.38 to 5.58 dollars, which includes an estimated 0.20 dollars of dilution related to the Exact Sciences transaction. For the second quarter of 2026, Abbott forecasts adjusted diluted EPS of 1.25 to 1.31 dollars.
By business segment, first-quarter Nutrition sales declined 6.0 percent on a reported basis and 7.7 percent on a comparable basis, reflecting lower volumes and the impact of pricing actions taken in late 2025. Diagnostics sales increased 6.1 percent reported and 1.8 percent comparable, driven by growth in Core Laboratory testing and the addition of Cancer Diagnostics, partially offset by lower Rapid and Molecular Diagnostics demand due to a weaker respiratory virus season. Established Pharmaceuticals grew 13.2 percent reported and 9.0 percent comparable, led by branded generics in key emerging markets. Medical Devices sales rose 13.2 percent reported and 8.5 percent comparable, with double-digit growth in Electrophysiology, Heart Failure, and Rhythm Management, and 14.2 percent reported growth in continuous glucose monitoring within Diabetes Care.
Abbott’s board of directors declared the company’s 409th consecutive quarterly dividend of 0.63 dollars per share, payable May 15, 2026, to shareholders of record as of April 15, 2026. Abbott has increased its annual dividend payout for 54 consecutive years and is a constituent of the S&P 500 Dividend Aristocrats Index.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!